Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen Inc (NQ: OCGN )

0.9575 +0.0082 (+0.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen Inc

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
32 33 Next >
7 Stocks to Short Before July 2022
There are many highly overvalued publicly traded companies that will have trouble staying afloat, giving investors many stocks to short. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022
Via Benzinga
Ocugen Diversifies Its Pipeline With New Cell Therapy Platform
Via Benzinga
OCGN Stock Falls Despite Positive FDA Update
Shares of the biotech company are falling despite news that the FDA has cleared it to resume clinical trials of its Covid-19 vaccine. 
Via InvestorPlace
FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial
Via Benzinga
The Top Reasons to Avoid the Ocugen Stock
WIth Ocugen, there’s nothing to get excited about here. Avoid the OCGN stock, as it heads significantly lower. 
Via InvestorPlace
Monitoring Board Gives Positive Recommendation On Ocugen's Eye Disease Gene Therapy Trial
Via Benzinga
Earnings Scheduled For May 6, 2022
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. 
Via Benzinga
Why Ocugen Shares Are Trading Higher Today
Via Benzinga
Why Is Ocugen (OCGN) Stock Down Today?
Shares of OCGN stock are trading lower after the FDA announced that it had placed a clinical hold on Covaxin. Here's what you should know. 
Via InvestorPlace
FDA Places Clinical Hold On Ocugen's Late-Stage COVID-19 Vaccine Trial
The  
Via Benzinga
Novavax Stock Could Give Back More of Its Pandemic-Era Gains
While trading at a very low multiple to the low end of earnings estimates, NVAX stock may still be trading at a premium. 
Via InvestorPlace
State Street Just Bought Ocugen (OCGN) Stock. Here’s Why.
OCGN stock has declined by over 90% in the past five years. However, that hasn't stopped State Street from more than doubling its position. 
Via InvestorPlace
Why Is Lixte Biotechnology (LIXT) Stock Up Today?
Lixte Biotechnology (LIXT) stock is rocketing higher on Tuesday after the company revealed pre-clinical results for one of its treatments. 
Via InvestorPlace
Here's Why Ocugen Shares Are Falling
Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 5.86% to $2.73 during Tuesday's pre-market session after the company announced that it was informed by the FDA that... 
Via Benzinga
What the WHO Snub Means For Ocugen Stock Investors?
Add the World Health Organization's suspension of Covaxin to the list of troubles that are weighing down OCGN stock. 
Via InvestorPlace
Read Why Did WHO Suspend UN Supply of Bharat Biotech's Covaxin COVID-19 Vaccine
Via Benzinga
Why Is Ocugen (OCGN) Stock Up 10% Today?
Sometimes, improved investor sentiment and a revamped website is enough of a catalyst to take something like OCGN stock on a 10% ride higher. 
Via InvestorPlace
Ocugen Is Two Strikes in With a Third in the Books
Ocugen failed to get energency use authorization for pediatric use of Covaxin. OCGN stock has tanked as a result. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today. 
Via InvestorPlace
26 Stocks Moving in Monday's Pre-Market Session
Gainers SPI Energy Co., Ltd. (NASDAQ: SPI) rose 36.3% to $3.87 in pre-market trading after reporting record revenue of $162 million for 2021. Twitter, Inc. (NYSE: TWTR) rose... 
Via Benzinga
These Were The 20 Most Searched Tickers On Benzinga In The First Quarter: Did Your Favorite Stock Make The List?
The first three months of 2022 are in the books, bringing the first quarter to a close. Investors were faced with many macro events, including rising inflation and the war in Ukraine. Benzinga was a... 
Via Benzinga
It’s Time to Get Clinical, Not Cynical, With Ocugen Stock
The selling pressure on OCGN stock has been as heavy as a rock, but worried shareholders should celebrate Ocugen's breakthrough moments. 
Via InvestorPlace
The Biggest Reasons to Avoid Ocugen for Now
Ocugen was one of the hottest stocks on the market. OCGN Stock soared from 18 cents to $17.6 back to about $2.5. Now, I wouldn’t touch it. 
Via InvestorPlace
Why Is Ocugen (OCGN) Stock Up Today?
Biotechnology company Ocugen is grabbing headlines today after jumping more than 15%. Is OCGN stock making a comeback? 
Via InvestorPlace
3 Market ETF Stocks to Buy This Week on Fed Jitters
The bears have two major tailwinds and the Fed is one. Here are 3 ETF stocks to buy into a potential relief rally after the event blows over. 
Via InvestorPlace
Is Sweetgreen Stock a Buy After Earnings? 3 Analysts Weigh In on SG.
Sweetgreen (SG) stock is rising as we check it with analysts following the fast-casual restaurants' most recent earnings report. 
Via InvestorPlace
43 Stocks Moving In Friday's Mid-Day Session
Gainers VEON Ltd. (NASDAQ: VEON) rose 45.6% to $0.3830 after dropping 41% on Thursday. Indonesia Energy Corporation Limited (NASDAQ: INDO) shares climbed 45.2% to $29.33 after... 
Via Benzinga
68 Biggest Movers From Friday
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares jumped 101.8% to close at $40.77 on Friday after jumping 39% on Thursday. Mexco Energy Corporation (NYSE: MXC... 
Via Benzinga
Is BABA Stock a Buy? 3 Analysts Weigh In on Alibaba.
Alibaba (BABA) stock is in the news lately with the company's shares slipping and we're seeing what experts have to say. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.